Welcome to our dedicated page for Veeva Systems news (Ticker: VEEV), a resource for investors and traders seeking the latest updates and insights on Veeva Systems stock.
Veeva Systems Inc. (NYSE: VEEV) is a global leader in cloud-based software solutions specifically tailored for the life sciences industry. Headquartered in the San Francisco Bay Area, Veeva Systems provides innovative technology that helps pharmaceutical and biotech companies streamline their operations, ensure compliance, and bring products to market faster. Veeva's product offerings address key operational and regulatory needs, ranging from customer relationship management (CRM) to content management and data analytics.
Two of the company's flagship products include Veeva CRM and Veeva Vault. Veeva CRM is designed for companies with a salesforce, providing tools to manage customer interactions more efficiently. Meanwhile, Veeva Vault is a versatile content management platform that supports various functions such as clinical trials, regulatory submissions, and quality management within life sciences companies.
Veeva serves a diverse customer base, ranging from emerging biotechs to some of the world's largest pharmaceutical companies. Its commitment to product excellence, customer success, and continuous innovation is evident as Veeva frequently updates its offerings to meet the evolving needs of the industry. Recently, Veeva announced that Boehringer Ingelheim has selected Veeva Vault Clinical and Veeva Vault RIM applications to streamline clinical execution and improve regulatory management in its animal health business unit.
Another notable achievement for Veeva was the launch of the Veeva AI Partner Program, designed to help partners integrate Generative AI solutions seamlessly with Veeva Vault applications. This initiative highlights Veeva's ongoing efforts to leverage advanced technologies to enhance its product ecosystem. Furthermore, the introduction of Veeva Vault CRM Campaign Manager aims to simplify and speed up non-personal promotion to healthcare professionals, ensuring consistent and compliant marketing efforts.
Financially, Veeva Systems has shown strong performance with its fiscal year 2024 results reflecting robust growth. The company continues to invest in its innovation engine and strategic partnerships, setting the stage for sustained, profitable growth. Veeva's recent financial outlook for fiscal year 2025 and first quarter results for 2024 further underline its market leadership and operational excellence.
For more information about Veeva Systems, its products, and latest updates, visit www.veeva.com.
Veeva Systems (NYSE: VEEV) announced the appointment of four new board members: Tim Cabral, Priscilla Hung, Tina Hunt, and Marshall Mohr, effective January 21, 2022. These individuals bring extensive experience in life sciences and enterprise software. Cabral, former CFO of Veeva, is now involved with ServiceTitan and Doximity. Hung leads operations at Guidewire Software, Hunt is an executive at IDEXX, and Mohr previously managed global business services at Intuitive. Ron Codd will retire from the board in June 2022 after a decade of service.
Veeva Systems announced that the Lymphoma Academic Research Organization (LYSARC) has chosen the Veeva Development Cloud to boost operational efficiency in lymphoma therapy research. LYSARC aims to integrate applications from Vault Clinical, Vault Quality, and Vault Safety into a cohesive platform for enhanced trial execution and data quality. This partnership will facilitate greater scalability and speed in developing innovative lymphoma treatments, impacting over 750 patients annually across regions including Belgium, France, and Portugal.
On December 14, 2021, Veeva Systems (NYSE: VEEV) announced PharmaEssentia's adoption of Veeva Data Cloud to aid in the launch of BESREMi, a novel therapy for polycythemia vera (PV). The platform will provide critical patient insights for targeting healthcare providers and analyzing patient journeys. PharmaEssentia's U.S. General Manager highlighted the platform's role in enhancing visibility of patient data, while Veeva's CEO emphasized its support for various analytics and workflow operations. The collaboration aims to improve HCP education about the new treatment.
Veeva Systems (NYSE: VEEV) has acquired Veracity Logic, a cloud software provider for randomization and trial supply management (RTSM). This acquisition aims to enhance Veeva's capabilities in streamlining complex clinical trial processes. The Veeva RTSM solution has already supported 175 trials across 60 countries. The integration will be managed by Veracity's founder, Steve Zimmerman, alongside key executives. Veeva emphasizes customer choice in integrating RTSM with various systems while maintaining existing partnerships. The forward-looking statements warn of the inherent risks in acquisitions.
Veeva Systems Inc. (NYSE: VEEV) reported impressive third-quarter results for fiscal 2022, with total revenues reaching $476.1 million, a 26% year-over-year increase. Subscription services revenues also rose by 26% to $380.7 million. Operating income increased by 31% to $132.7 million, while net income grew by 9% to $105.9 million. The company provided strong guidance for the fiscal fourth quarter, projecting total revenues of $478 to $480 million and a non-GAAP net income per share of approximately $0.88. Veeva's focus on innovation and customer success positions it for continued growth.
Veeva Systems (NYSE: VEEV) introduced enhancements to Veeva CRM at the European Veeva Commercial and Medical Summit on November 18, 2021. These updates cater to the evolving dynamics of healthcare professional (HCP) engagement by providing a simplified experience for in-person and digital channels. Key features include device flexibility, role-based applications, and tailored workflows, allowing field teams to operate efficiently across various devices. Veeva CRM is utilized by 42 of the top 50 pharmaceutical firms, underscoring its industry position.
Veeva Systems announced the launch of Veeva CRM Engage Connect at the European Veeva Commercial and Medical Summit on November 18, 2021. This new feature enhances compliant messaging and content sharing for healthcare professionals (HCPs) through the Veeva Engage app, used by over one million HCPs. Engage Connect enables direct communication between HCPs and life sciences companies, providing resources and scheduling options, facilitating a more personal interaction.
Available next month, this innovation aims to improve engagement and support patient care.
On Nov. 16, 2021, Veeva Systems (NYSE: VEEV) announced that the Center for Breakthrough Medicines (CBM) adopted the Veeva Vault Quality Suite to enhance development and manufacturing services for cell and gene therapies. The partnership aims to streamline quality processes and accelerate the delivery of therapies. CBM, a CDMO, focuses on increasing access to advanced therapies. The Veeva Vault Quality Suite will enable CBM to harmonize quality processes, boost efficiency, and improve collaboration across its manufacturing network, supporting its goal of establishing a leading therapy manufacturing facility.
Veeva Systems will announce its third fiscal quarter results for 2022 on December 1, 2021, after market close. The company will hold a conference call at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results. Prepared remarks will be available on its investor relations website approximately 55 minutes before the call. Veeva, a leader in cloud software for the life sciences sector, serves over 1,000 customers worldwide, including major pharmaceutical companies and emerging biotechs.
FAQ
What is the current stock price of Veeva Systems (VEEV)?
What is the market cap of Veeva Systems (VEEV)?
What does Veeva Systems Inc. do?
Where is Veeva Systems Inc. headquartered?
What are Veeva's main products?
Who are Veeva Systems' customers?
What recent partnerships has Veeva announced?
What is the Veeva AI Partner Program?
How has Veeva performed financially recently?
What is Veeva Vault CRM Campaign Manager?
What industry does Veeva Systems primarily serve?
How does Veeva contribute to the life sciences industry?
